Response to second-line and beyond therapies for MPN-AP/BP
| Therapy . | 2017 ELN response . | 2012 MPN-BP response . |
|---|---|---|
| DNMTi + VEN based (n = 38) | CR: 5% CRi: 5% MLFS: 16% PR: 5% SD: 13% TF: 55% | CCR: 3% ALR-C: 22% ALR-P: 14% SD: 22% PD: 39% |
| (n = 38 evaluable for ELN) | ||
| (n = 36 evaluable for MPN-BP) | ||
| IC (n = 37) | CR: 16% CRi: 3% MLFS: 14% PR: 11% SD: 19% TF: 38% | CCR: 6% ALR-C: 15% ALR-P: 29% SD: 21% PD: 29% |
| (n = 37 evaluable for ELN) | ||
| (n = 34 evaluable for MPN-BP) | ||
| DNMTi based (n = 16) | CR: 6% MLFS: 6% PR: 6% SD: 25% TF: 56% | ALR-C: 14% ALR-P: 21% SD: 29% PD: 36% |
| (n = 16 evaluable for ELN) | ||
| (n = 14 evaluable for MPN-BP) | ||
| Targeted monotherapy (n = 11) | CR: 9% CRi: 18% MLFS: 18% SD: 18% TF: 36% | CCR: 10% ALR-C: 30% ALR-P: 20% SD: 20% PD: 20% |
| (n = 11 evaluable for ELN) | ||
| (n = 10 evaluable for MPN-BP) | ||
| Other therapies (n = 13) | CR: 8% CRi: 8% PR: 23% SD: 38% TF: 23% | ALR-C: 15% ALR-P: 31% SD: 31% PD: 23% |
| (n = 13 evaluable for ELN) | ||
| (n = 13 evaluable for MPN-BP) |
| Therapy . | 2017 ELN response . | 2012 MPN-BP response . |
|---|---|---|
| DNMTi + VEN based (n = 38) | CR: 5% CRi: 5% MLFS: 16% PR: 5% SD: 13% TF: 55% | CCR: 3% ALR-C: 22% ALR-P: 14% SD: 22% PD: 39% |
| (n = 38 evaluable for ELN) | ||
| (n = 36 evaluable for MPN-BP) | ||
| IC (n = 37) | CR: 16% CRi: 3% MLFS: 14% PR: 11% SD: 19% TF: 38% | CCR: 6% ALR-C: 15% ALR-P: 29% SD: 21% PD: 29% |
| (n = 37 evaluable for ELN) | ||
| (n = 34 evaluable for MPN-BP) | ||
| DNMTi based (n = 16) | CR: 6% MLFS: 6% PR: 6% SD: 25% TF: 56% | ALR-C: 14% ALR-P: 21% SD: 29% PD: 36% |
| (n = 16 evaluable for ELN) | ||
| (n = 14 evaluable for MPN-BP) | ||
| Targeted monotherapy (n = 11) | CR: 9% CRi: 18% MLFS: 18% SD: 18% TF: 36% | CCR: 10% ALR-C: 30% ALR-P: 20% SD: 20% PD: 20% |
| (n = 11 evaluable for ELN) | ||
| (n = 10 evaluable for MPN-BP) | ||
| Other therapies (n = 13) | CR: 8% CRi: 8% PR: 23% SD: 38% TF: 23% | ALR-C: 15% ALR-P: 31% SD: 31% PD: 23% |
| (n = 13 evaluable for ELN) | ||
| (n = 13 evaluable for MPN-BP) |
Abbreviations are explained in Table 3.